Severe acute respiratory syndrome-related coronavirus

AIkido Pharma Inc. Announces Key Progress in Computational Approaches to Identify Virus Treatments, Including Coronavirus

Retrieved on: 
Thursday, July 9, 2020
Viruses, Infectious diseases, Medicine, Zoonoses, Coronaviridae, Health in Saudi Arabia, In Saudi Arabia, Coronavirus, Influenza, Antiviral drug, Middle East respiratory syndrome-related coronavirus, Severe acute respiratory syndrome-related coronavirus

NEW YORK, July 9, 2020 /PRNewswire/ --AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on its effort to identify compounds to potentially address the COVID-19 pandemic.

Key Points: 
  • NEW YORK, July 9, 2020 /PRNewswire/ --AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on its effort to identify compounds to potentially address the COVID-19 pandemic.
  • These compounds were tested for their ability to block replication of the Influenza virus in human cells, from which several active compounds were found.
  • "This is encouraging progress, demonstrating the importance of machine learning to accelerate pharmaceutical research," commented Anthony Hayes, CEO of AIkido.
  • The Company is also developing a broad spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

EpiGentek Releases First-to-Market Kits to Detect SARS-CoV-2-Targeted Furin Activity and Screen for Inhibitors Against COVID-19

Retrieved on: 
Thursday, July 9, 2020
Enzymes, Proprotein convertase, Zoonoses, Furin, Branches of biology, Severe acute respiratory syndrome-related coronavirus, Protease, Severe acute respiratory syndrome, Medicine, Health

The two kits focus on studies of SARS-CoV-2 targeted furin or proprotein convertase (PC) cleavage activity.

Key Points: 
  • The two kits focus on studies of SARS-CoV-2 targeted furin or proprotein convertase (PC) cleavage activity.
  • These first-of-its-kind tools can be used to rapidly detect SARS-CoV-2 targeted PC and facilitated proteases using biological samples as well as screen for inhibitors of these enzymes that cleave SARS-CoV-2 proteins.
  • The first of the two kits by EpiGentek, CoviDrop(TM) SARS-CoV-2 Targeted Proprotein Convertase Inhibitor Screening Fast Kit (Catalog No.
  • EpiGentek has also recently released a series of other assay kits to rapidly detect SARS-CoV-2 neutralizing antibodies and measure spike-ACE2 binding activity or inhibition.

Ardigen Enters Into Research Collaboration With CVC to Apply Artificial Intelligence for Identification of T-cell Targets

Retrieved on: 
Thursday, July 9, 2020
Medical specialties, Branches of biology, Medicine, Immune system, Immunology, Biotechnology, Antigen, Biomolecules, Epitope, Polyclonal antibodies, Severe acute respiratory syndrome-related coronavirus, Vaccine

KRAKW, Poland and AUCKLAND, New Zealand, July 9, 2020 /PRNewswire/ -- Ardigen and CVC announced that they entered a research collaboration aimed at the development of SARS-CoV-2 vaccine.

Key Points: 
  • KRAKW, Poland and AUCKLAND, New Zealand, July 9, 2020 /PRNewswire/ -- Ardigen and CVC announced that they entered a research collaboration aimed at the development of SARS-CoV-2 vaccine.
  • The core of the platform is a proprietary algorithm capable of predicting neoantigens' probability to elicit an immune response.
  • This joint research enables CVC to benefit from Ardigen's vaccine design technology by selecting which viral epitopes are the most suitable to boost cellular immune response.
  • Robert Feldman, CEO and Co-founder of CVC, adds: "CVC is excited to be working with Ardigen who are at the forefront of T-cell epitope design.

Ardigen Enters Into Research Collaboration With CVC to Apply Artificial Intelligence for Identification of T-cell Targets

Retrieved on: 
Thursday, July 9, 2020
Medical specialties, Branches of biology, Medicine, Immune system, Immunology, Biotechnology, Antigen, Biomolecules, Epitope, Polyclonal antibodies, Severe acute respiratory syndrome-related coronavirus, Vaccine

KRAKW, Poland and AUCKLAND, New Zealand, July 9, 2020 /PRNewswire/ -- Ardigen and CVC announced that they entered a research collaboration aimed at the development of SARS-CoV-2 vaccine.

Key Points: 
  • KRAKW, Poland and AUCKLAND, New Zealand, July 9, 2020 /PRNewswire/ -- Ardigen and CVC announced that they entered a research collaboration aimed at the development of SARS-CoV-2 vaccine.
  • The core of the platform is a proprietary algorithm capable of predicting neoantigens' probability to elicit an immune response.
  • This joint research enables CVC to benefit from Ardigen's vaccine design technology by selecting which viral epitopes are the most suitable to boost cellular immune response.
  • Robert Feldman, CEO and Co-founder of CVC, adds: "CVC is excited to be working with Ardigen who are at the forefront of T-cell epitope design.

R+D Custom Automation Has Announced an Agreement with SiO2 Materials Science

Retrieved on: 
Thursday, July 9, 2020
Viruses, Health, Zoonoses, Animal diseases, Coronaviridae, Animal virology, Health in Saudi Arabia, In Saudi Arabia, Severe acute respiratory syndrome-related coronavirus, Silicon dioxide, CoV, Middle East respiratory syndrome-related coronavirus

LAKE VILLA, Ill., July 9, 2020 /PRNewswire/ --R+D Custom Automation, a privately-owned U.S. provider of fully customized automation systems, has announced an agreement with SiO2 Materials Science.

Key Points: 
  • LAKE VILLA, Ill., July 9, 2020 /PRNewswire/ --R+D Custom Automation, a privately-owned U.S. provider of fully customized automation systems, has announced an agreement with SiO2 Materials Science.
  • SiO2, a privately-owned U.S. advanced materials science corporation, was recently awarded a $143 million contract with the federal government as part of the Operation Warp Speed initiative.
  • The agreement accelerates the production of SiO2's patented plastic vials for storing novel coronavirus (SARS-CoV-2) vaccines and therapeutics.
  • According to Lawrence Ganti, President of Customer Operations at SiO2, the SiO2 vials are the only alternative to glass.

ChromaDex Announces New Study Results Highlighting Promising Anti-Viral Effects of Niagen® in Coronavirus Cell Model

Retrieved on: 
Thursday, July 9, 2020
University, Stem cells, Pharmaceutical, Education, General Health, Infectious diseases, Genetics, Fitness & Nutrition, Clinical trials, Science, Biotechnology, Alternative medicine, Other Science, Health, Research, Viruses, Animal virology, Zoonoses, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Antiviral drug, Severe acute respiratory syndrome, Coronaviridae

These latest results confirmed their hypothesis by demonstrating that cell lines infected with a type of Coronavirus had decreased viral replication when supplemented with NR.

Key Points: 
  • These latest results confirmed their hypothesis by demonstrating that cell lines infected with a type of Coronavirus had decreased viral replication when supplemented with NR.
  • The collaborative research team also found that the activity of antiviral PARP enzymes was upregulated by boosting NAD pharmacologically.
  • The next steps are animal and human trials against SARS-CoV-2, reports Dr. Charles Brenner, a co-author of the study and ChromaDex Chief Scientific Advisor.
  • The team of investigators used a multi-pronged approach involving a form of Coronavirus and performed experiments in multiple separate cell models.

Applied DNA Forms Clinical Testing Subsidiary to Maximize Utility of FDA EUA-Approved Linea™ COVID-19 Assay Kit and Expands Utility with Successful EUA Amendment

Retrieved on: 
Thursday, July 9, 2020
Infectious diseases, Genetics, Clinical trials, Stem cells, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Oncology, Viruses, Natural sciences, Nidovirales, Laboratory techniques, Coronaviridae, Zoonoses, Animal virology, Molecular biology, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Emergency Use Authorization, Severe acute respiratory syndrome

In mid-May, Applied DNA received Emergency Use Authorization (EUA) for a high sensitivity, high-throughput complex molecular test for SARS-CoV-2, the coronavirus that causes COVID-19.

Key Points: 
  • In mid-May, Applied DNA received Emergency Use Authorization (EUA) for a high sensitivity, high-throughput complex molecular test for SARS-CoV-2, the coronavirus that causes COVID-19.
  • The Linea COVID-19 SARS-CoV-2 Assay Kit is a real-time polymerase chain reaction (RT-PCR) test for the qualitative detection of SARS-CoV-2 RNA in respiratory specimens.
  • It provides a high-throughput solution to help laboratories address the urgent need for patient testing during the Coronavirus pandemic.
  • ADCL, the Companys new subsidiary was formed to enable clinical testing of patient specimens using methods developed by the Companys research teams.

PathSensors receives expanded license from MIT for CANARY Technology

Retrieved on: 
Thursday, July 9, 2020
Biosensors, Articles, Biotechnology, Academic disciplines, Bioinformatics, Sensor, Severe acute respiratory syndrome-related coronavirus, Sensitivity and specificity, Life sciences, Severe acute respiratory syndrome

BALTIMORE, July 9, 2020 /PRNewswire-PRWeb/ --PathSensors Inc., a Baltimore biotechnology company, announced today that Massachusetts Institute of Technology (MIT) has expanded the company's exclusive license to include clinical applications for CANARY technology.

Key Points: 
  • BALTIMORE, July 9, 2020 /PRNewswire-PRWeb/ --PathSensors Inc., a Baltimore biotechnology company, announced today that Massachusetts Institute of Technology (MIT) has expanded the company's exclusive license to include clinical applications for CANARY technology.
  • This broader license allows PathSensors to move into the point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor.
  • "PathSensors originally developed CANARY technology for commercial use in 2012," stated PathSensors' President, Ted Olsen.
  • CANARY is a biosensor technology that delivers extremely rapid detection of pathogens with high sensitivity and specificity.

UK Real Estate Company Hondo Enterprises in Partnership With Savills to Use BioProtectUs™ System in United Kingdom

Retrieved on: 
Thursday, July 9, 2020
Viruses, Coronaviridae, Zoonoses, Animal virology, CoV, Coronavirus, Savills, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, In Saudi Arabia

LONDON, July 9, 2020 /PRNewswire/ --Hondo Enterprises, in partnership with Savills, has become the first and only company in the United Kingdom to utilise the BIOPROTECTUs system offered by BioSupplies.com, LLC in the United Kingdom.

Key Points: 
  • LONDON, July 9, 2020 /PRNewswire/ --Hondo Enterprises, in partnership with Savills, has become the first and only company in the United Kingdom to utilise the BIOPROTECTUs system offered by BioSupplies.com, LLC in the United Kingdom.
  • The system, which features a water-based anti-microbial called BIOPROTECT, was independently verified by a third party to eradicate SARS-CoV-2 from surfaces for more than six weeks.
  • SARS-CoV-2 is the unique coronavirus that causes COVID-19.
  • Hondo Enterprises is a property investment, development and asset management company specialising in transactions in Central London.

UK Real Estate Company Hondo Enterprises in Partnership With Savills to Use BioProtectUs™ System in United Kingdom

Retrieved on: 
Thursday, July 9, 2020
Viruses, Coronaviridae, Zoonoses, Animal virology, CoV, Coronavirus, Savills, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, In Saudi Arabia

LONDON, July 9, 2020 /PRNewswire/ --Hondo Enterprises, in partnership with Savills, has become the first and only company in the United Kingdom to utilise the BIOPROTECTUs system offered by BioSupplies.com, LLC in the United Kingdom.

Key Points: 
  • LONDON, July 9, 2020 /PRNewswire/ --Hondo Enterprises, in partnership with Savills, has become the first and only company in the United Kingdom to utilise the BIOPROTECTUs system offered by BioSupplies.com, LLC in the United Kingdom.
  • The system, which features a water-based anti-microbial called BIOPROTECT, was independently verified by a third party to eradicate SARS-CoV-2 from surfaces for more than six weeks.
  • SARS-CoV-2 is the unique coronavirus that causes COVID-19.
  • Hondo Enterprises is a property investment, development and asset management company specialising in transactions in Central London.